Author Archives: admin


Stem Cell Clinic > Articles by: admin

Hematopoietic Stem Cells Transplantation (HSCT) Market: Future Innovation Ways That, Growth & Profit Analysis, Forecast By 2026 – 3rd Watch News

By Stem Cell Treatment

Hematopoietic Stem Cells Transplantation (HSCT) Marketreport provides in-depth COVID19 impact analysis ofMarket Overview, Product Scope, Market Drivers, Trends, Opportunities,Market Driving Force and Market Risks. It also profile the topmost prime manufacturers (Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems) are analyzed emphatically by competitive landscape contrast, with respect toPrice, Sales,Capacity, Import, Export, Consumption, Gross, Gross Margin, Revenue and Market Share. Hematopoietic Stem Cells Transplantation (HSCT) industry breakdown data are shown at the regional level, to show the sales, revenue and growth by regions.Hematopoietic Stem Cells Transplantation (HSCT) Market describe Hematopoietic Stem Cells Transplantation (HSCT) Sales Channel,Distributors, Customers, Research Findings and Conclusion, Appendix and Data Source.

Key Target Audience of Hematopoietic Stem Cells Transplantation (HSCT) Market:Manufacturers of Hematopoietic Stem Cells Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cells Transplantation (HSCT) market.

Get Free Sample PDF (including full TOC, Tables and Figures)of Hematopoietic Stem Cells Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2039940

In-Depth Qualitative Analyses Include Identification and Investigation Of The Following Aspects:Hematopoietic Stem Cells Transplantation (HSCT) Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces.

Summary of Hematopoietic Stem Cells Transplantation (HSCT) Market:Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.

Over 30 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.

Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patients overall health. There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Hematopoietic Stem Cells Transplantation (HSCT) market foreach application, including-

Leukemia Lymphoproliferative Disorders Solid Tumors Non-Malignant Disorders Others

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type, primarily split into-

Autologous Transplant Allogenic Transplant

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2039940

Important Hematopoietic Stem Cells Transplantation (HSCT) Market Data Available In This Report:

Contact:

ResearchMoz Mr. Rohit Bhisey, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

Original post:
Hematopoietic Stem Cells Transplantation (HSCT) Market: Future Innovation Ways That, Growth & Profit Analysis, Forecast By 2026 - 3rd Watch News

Vor bags $110M to move engineered cell therapy into the clinic – FierceBiotech

By Stem Cell Clinic

CAR-T treatments and other immunotherapies have changed the treatment of some blood cancers, but they can target healthy cells as well as cancer cells, causing nasty side effects. Vor Biopharma is working on an engineered stem cell solution, and its raised $110 million to move its lead program into the clinic.

The Cambridge, Massachusetts-based company is developing the treatment, VOR33, for patients with acute myeloid leukemia (AML) whose disease has worsened despite undergoing chemotherapy or a stem cell transplant.

Thats the setting in which a lot of targeted agents are used. The trouble is, a great number of the targeted agents tend to failnot because they are not efficacious, but because the drug is too toxic for the patients bone marrow, Vor CEO Robert Ang told Fierce Biotech.

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

The drugs home in on healthy cells as well as cancerous ones because they express the same proteins. This leads to myelosuppression, which means the bone marrow doesnt make enough white blood cells, platelets or red blood cells for the patient to survive, Ang said.

RELATED: Neon CBO Robert Ang jumps ship to take the helm at Vor Biopharma

Vors treatment is made from hematopoietic, or blood-forming, stem cells from healthy donors. The company uses gene editing to get rid of cancer drug targets in those cells that are biologically redundant, which means deleting them doesnt cause any harm. That target is CD33, in the case of VOR33.

Were trying to make the marrow treatment resistant such that the only cells that are expressing CD33 should be cancer cells, Ang said. We should be able to target them much more specifically, while minimizing the collateral damage that typically happens with these drugs.

RELATED: 5AM, JJDC get in on $42M series A round for cell therapy player Vor Biopharma

Vor believes its treatments could boost the reach of targeted therapies by improving their efficacy and increasing the amount of time patients can undergo those treatments.

And thats not all. In addition to protecting these transplants and the blood cells they produce from targeted drugs, Vor thinks its approach could change the way we think about bone marrow transplant.

To some degree, transplants have been relatively decentralized and less controlled A lot of hospitals develop their own unique practices as to what they think works and how to handle cells and process them, Ang said. Our product will be regulated by the FDA, so we will be able to provide controls and the proper manufacturing steps to ensure were making the best quality product for patients.

The series B will push VOR33 into clinical trials in the first half of 2021, a target the companys on track to meet despite the COVID-19 pandemic. And Vor plans to expand its portfolio beyond CD33, starting with an umbrella of targets in the myeloid space, namely in acute myeloid leukemia, myelodysplastic syndromes and related diseases.

But we are also looking beyond that to other cancers where there are similar potentially biologically redundant targets we could pursue, said Ang, who took the companys helm in August 2019.

Since then, Vor has grown from a staff of six to 50, and its about to move into new digs in west Cambridge as it moves VOR33 toward the clinic. Its got the backing of RA Capital Management, Fidelity, 5AM Ventures, Johnson & Johnson Innovation, Osage University Partners, PureTech Health, the Pagliuca Family Office and Alexandria Venture Investments to do it all.

Read more from the original source:
Vor bags $110M to move engineered cell therapy into the clinic - FierceBiotech

Politicians Turn Their Backs on Public Safety and Will Want More of Your Money in November – City Watch

By Stem Cell Clinic

RANTZ & RAVEZ-Los Angeles Mayor Eric Garcetti (who called police officers killers) and City Councilmembers responded to the demands of protestors and rioters by slashing $150 million from the 2020-2021 LAPD budget.

LAs taxpaying residents and business owners were ignored by city officials who continue to permit the city to turn more neighborhoods into homeless camps with expanding decay and rising violent crime trends.

All but two voting councilmembers approved Garcettis 2020-2021 city budget which took $150 million from the LAPD and passed it to various organizations that serve minority communities in LA. Following the hatchet job on the LAPDs budget, the council adjourned, canceling future July meetings in order to go on a near month-long summer recess. This is happening while our City is on semi-lockdown due to the coronavirus that is spreading and infecting more people in the region and other American cities.

The FBI continues to investigate elected and appointed officials at City Hall, and two elected councilmembers have already been arrested; one has agreed to go to prison without a trial. A cloud of suspicion remains over the question of when the next arrest or arrests will occur as the investigation of illegal activity, bribes, and corruption continues to be conducted by FBI agents.

While members of the council enjoy their extended summer vacation and annual salary of over $207,000, the taxpayers of Los Angeles continue to struggle to find jobs, pay bills and find funds to repair the damages caused by the recent riots in large sections of the city. The lack of leadership and support displayed by the Mayor and Councilmembers for the LAPD and people of LA is truly a sad situation for Angelenos.

While the majority of the council voted to slash $150 million in public safety funds from the police budget, only two councilmembers had the courage to stand up to the anti-police groups calling for the financial reduction and redistribution to other causes. Councilmembers John Lee from the 12th District in the San Fernando Valley and Joe Buscaino from CD 15 in South Los Angeles and San Pedro. The rest of the council followed the lead of our spineless mayor and those pushing for the reduction in police funding. Keep this in mind when you call 911 in the future and there is a delay in the response time of officers.

Remember the names of the councilmembers who have turned their backs on public safety for all people in Los Angeles. Remember them when they ask you to vote for new tax increases which will appear on future ballots. Since they have turned their backs on public safety for you and your family, they might be better suited to find jobs in the private sector. I will remind you of those names this November and in future years. They do not deserve your votes.

On the subject of the November 3 election, let me share what Sacramento officials have in store for you and your wallets on the statewide ballot. There are currently 12 propositions that have qualified for the November election.

It is time to clean your guns and purchase fresh ammo. Be prepared to protect yourself and your family as we approach November and the state and national elections.

(Dennis P. Zine is a native of Los Angeles who retired from the LAPD after serving 33 years. Dennis remains an active Level 1 LAPD Reserve Officer. Dennis served for two years as the vice chairman on the Elected Los Angeles City Charter Reform Commission and was a member of the Los Angeles City Council for 12 years.) Edited for CityWatch by Linda Abrams.

Read the original:
Politicians Turn Their Backs on Public Safety and Will Want More of Your Money in November - City Watch

In the middle of pandemic, this young mom fights second cancer diagnosis – INFORUM

By Stem Cell Clinic

Two years ago, Bustos was happy. She was 20, recently married and had just found out she was pregnant with her first child. Taylor and her husband, Mark, 21, envisioned moving from Duluth to California and raising half a dozen kids. But those plans would have to wait.

Five months into her pregnancy, Bustos felt a lump on her neck. On Oct. 5, 2018, just a month after giving birth to her son, Solomon, she was diagnosed with nodular sclerosis classical Hodgkins lymphoma. Its the most common type of Hodgkins lymphoma, a cancer that affects the bodys immune system.

I was told, This is the good cancer, its curable, Bustos said. She underwent six months of chemotherapy at St. Lukes Radiation Oncology Associates in Duluth and was declared in remission in April 2019. After that, life went pretty much back to normal.

But last November, just before her first follow-up PET CT scan, Bustos prepared for the worst. A few weeks earlier, she had felt the lump in her neck return.

Soon later, she was back at St. Lukes, prepared to receive whatever news may come. Mark tossed a bright pink ball to Solomon to distract the boy and himself from the mounting anxiety as they waited for what felt like an eternity in the small examination room.

The young father was also trying to manage his stress from recently learning he was being laid off from his construction job. The doctor finally stepped in.

Taylor and Mark shared a kiss in their kitchen, taking any quiet moment they can to show their love to one another while raising a one-year-old. Taylor had been diagnosed with Hodgkin's Lymphoma only a month after giving birth to their first son, Solomon. She had just spent the better part of a year battling cancer and was now cancer free. So she was trying to enjoy any sense of normalcy she could. Alex Kormann / Minneapolis Star Tribune/TNS

Im sitting there with a one-year-old and my husband of two years and theyre telling me at 22 years old that I have cancer for the second time, Bustos said.

She had gone into the meeting with the mindset that she would never endure chemotherapy again. It was physically and mentally unlike any other suffering Ive ever gone through in my life and I didnt want to willingly say yes to going back there, Bustos said.

After a week of thinking and praying, Bustos stumbled across a Facebook post from a friend who had recently lost his father in a house fire. His words resonated so deeply with her that she decided she couldnt just lay down and die. This cancer could kill me, but dont I want my sweet son to know I tried? she said.

Once again, she went in for treatments, then slept for three days. The big difference this time was that, to make sure the cancer never came back, she was going to have to follow the doctors next recommendation.

On March 2, the Bustos family picked up and moved 200 miles across the state to Rochester for three months where she would undergo some of the most toxic chemotherapy available at the Mayo Clinic. The mix was so potent that she had to first undergo a stem cell collection; those stem cells would be transplanted afterward to regrow her immune system and other healthy cells decimated by the chemo.

Marks layoff, which at first seemed like a disaster, was now a gift. He could assume a larger role as the family caretaker. Some people might call that luck, but the Bustoss dont believe in luck. For them, it was an act of God.

When it came time to move, Taylors parents, Pam and Jerry, who live across the street from the Bustoses in Duluth, moved with them to help take care of Solomon and Taylor.

It really wasnt a difficult decision, said Jerry, who is a warehouse operator at a Duluth paper supply business.

For me, he said, I would do whatever it takes to get her healthy.

The whole family joined hands and prayed before dinner. God and faith are extremely important to them and has helped Taylor get through this difficult chapter in her life. The COVID-19 pandemic forced church to be held via live stream so Taylor was able to follow along even from 200 miles away. Her faith helped Taylor push through even the darkest moments of treatment. "Knowing I'm in the hands of such a faithful father made it peaceful," she said. Alex Kormann / Minneapolis Star Tribune/TNS

Their family squeezed as much as they could into their two cars, boxes stacked to the roof, rendering the rearview mirror useless. The family settled into a small house only a mile away from the Mayo Clinic.

Just over a week later, COVID-19 hit.

We knew Id have a weakened immune system and wed have to quarantine, Bustos said, but suddenly the whole world had to quarantine, too.

They stayed closely connected with their church through video chat and live streams. In solidarity, her entire family shaved their heads along with Bustos.

A little over a month after moving, Bustos prepared for her most difficult round of chemotherapy. All the effects of normal chemo, including nausea, exhaustion, loss of appetite and body pain would be amplified. And because of the coronavirus, she would be doing it alone. She packed her keyboard piano, a weeks worth of clothes, a few mementos from home and headed to the hospital. She would have to stay in a heavily filtered room by herself for a full week as she underwent treatment.

Masked nurses came and went as Bustos tried to picture what they looked like under all the PPE. Most days, she felt immensely lonely and sad. Originally, she was told shed be able to go home to see her family for one hour per day. The pandemic scrapped those plans. I would cry and nurses couldnt put their hand on my shoulder to tell me, Its OK, because of the coronavirus, Bustos said.

When she was finally able to return to her family a full week later, Bustos was ecstatic. To be able to be hugged was a very welcome relief from despair, she said.

She began to try and process what had happened to her over the last five months. She felt distant from and misunderstood by nearly everyone around her. It can look like its going well from the outside but when you literally want to die, the emotional side of things needs to be handled, she said.

Bustos has since begun therapy and is taking anti-depressants to help manage her mental pain.

As the family moved out of Rochester, the snow was gone. Birds chirped and flowers bloomed; a sign of rebirth and a new beginning.

When they pulled up in front of their apartment in Duluth, chalk drawings graced their sidewalk welcoming them home. Their front door was covered in balloons and a welcome banner was strung across the door frame, all put together by members of Bustoss church youth group.

Bustos collapsed on her old bed. She thought shed feel different in their own apartment, but it oddly felt the same. She had come to realize that home was no longer a physical space. Cancer changed that.

Home for me has become Mark and Solomon, she said, and so whether were in Rochester, Duluth or Timbuktu, Im home when Im with them.

2020 Star Tribune (Minneapolis)

Visit the Star Tribune (Minneapolis) at http://www.startribune.com

Distributed by Tribune Content Agency, LLC.

Read the original post:
In the middle of pandemic, this young mom fights second cancer diagnosis - INFORUM

Radiation Response of Murine Embryonic Stem Cells

By Embryonic Stem Cells

To understand the mechanisms of disturbed differentiation and development by radiation, murine CGR8 embryonic stem cells (mESCs) were exposed to ionizing radiation and differentiated by forming embryoid bodies (EBs). The colony forming ability test was applied for survival and the MTT test for viability determination after X-irradiation. Cell cycle progression was determined by flow cytometry of propidium iodide-stained cells, and DNA double strand break (DSB) induction and repair by H2AX immunofluorescence. The radiosensitivity of mESCs was slightly higher compared to the murine osteoblast cell line OCT-1. The viability 72 h after X-irradiation decreased dose-dependently and was higher in the presence of leukemia inhibitory factor (LIF). Cells exposed to 2 or 7 Gy underwent a transient G2 arrest. X-irradiation induced H2AX foci and they disappeared within 72 h. After 72 h of X-ray exposure, RNA was isolated and analyzed using genome-wide microarrays. The gene expression analysis revealed amongst others a regulation of developmental genes (Ada, Baz1a, Calcoco2, Htra1, Nefh, S100a6 and Rassf6), downregulation of genes involved in glycolysis and pyruvate metabolism whereas upregulation of genes related to the p53 signaling pathway. X-irradiated mESCs formed EBs and differentiated toward cardiomyocytes but their beating frequencies were lower compared to EBs from unirradiated cells. These results suggest that X-irradiation of mESCs deregulate genes related to the developmental process. The most significant biological processes found to be altered by X-irradiation in mESCs were the development of cardiovascular, nervous, circulatory and renal system. These results may explain the X-irradiation induced-embryonic lethality and malformations observed in animal studies.

See the rest here:
Radiation Response of Murine Embryonic Stem Cells

Human Embryonic Stem Cells (HESC) Market Growth By Manufacturers, Type And Application, Forecast To 2026 – 3rd Watch News

By Embryonic Stem Cells

Others

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=218035&utm_source=3WN&utm_medium=888

The Human Embryonic Stem Cells (HESC) market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Human Embryonic Stem Cells (HESC) market.

This study analyzes the growth of Human Embryonic Stem Cells (HESC) based on the present, past and futuristic data and will render complete information about the Human Embryonic Stem Cells (HESC) industry to the market-leading industry players that will guide the direction of the Human Embryonic Stem Cells (HESC) market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Human Embryonic Stem Cells (HESC) market. Additionally, it includes a share of each segment of the Human Embryonic Stem Cells (HESC) market, giving methodical information about types and applications of the market.

Reasons for Buying Human Embryonic Stem Cells (HESC) Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Human Embryonic Stem Cells (HESC) market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=218035&utm_source=3WN&utm_medium=888

In the end, the Human Embryonic Stem Cells (HESC) market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Human Embryonic Stem Cells (HESC) market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Intelligent Network Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Medical Device Connectors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Plant Based Protein Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Property Management Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Road Compactor Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Visit link:
Human Embryonic Stem Cells (HESC) Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 – Jewish Life News

By Embryonic Stem Cells

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy. The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics. The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy. The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately. Use-type Insights The clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients. In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment. On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products. Therapy Type Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation. However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market. In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine. Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development. Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development. Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research Report This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

By Cell Type

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-stem Cell Therapies

Research-use

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Allogeneic Therapies

Autologous Therapies

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

Read the original:
Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Jewish Life News

Why we still haven’t cloned humans it’s not just ethics – Business Insider – Business Insider

By Embryonic Stem Cells

Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Following is a transcript of the video.

Narrator: We've been able to clone human embryos for about seven years. But as far as we know, no one's actually cloned a whole person. Turns out, ethics aren't the only thing holding scientists back. Cloning isn't the sci-fi marvel we think it is. It can be dangerous, often ineffective, and, most of all, we just haven't thought of a good enough reason to do it. So, here's why you'll probably never have to fight your evil clone.

This is Dolly. Just kidding, that's a regular sheep. This is Dolly, the first mammal cloned successfully from an adult cell. She was born in 1996 after scientists figured out how to remove the DNA from the egg cell of a Scottish Blackface sheep and basically replace it with the DNA of a mammary cell from a Finn Dorset sheep. They gave it a little electric shock to fuse the cell and get it replicating, placed the cells in the uterus of another sheep, and boom, clone. This method, called reproductive cloning, could theoretically be used on humans. But this is a best-case scenario. It took 277 tries for the scientists to get one Dolly. Nowadays, cloning mammals generally has a success rate of about 10% to 20%. Better than one in 277, but still a majorly inefficient process.

Jose Cibelli: Technically, it's not difficult to produce a clone embryo, but human cloning has other hurdles that need to be considered.

Narrator: To even research human cloning, scientists would need to ethically collect a large amount of donated eggs and find enough surrogates to carry them. But even if they made it through that logistical nightmare, the biggest issue is this:

Cibelli: They're gonna hurt the baby, or they're gonna hurt the person carrying the cloned fetus.

Narrator: Across the board, scientists have found that some embryos expire before they're implanted. Others result in miscarriages. And those that make it to term often die soon after birth or end up with severe abnormalities. Simply, these are risks that are easier to take when it comes to experimenting with sheep than with people. But arguably the biggest reason we haven't cloned a human being? There's not a good enough reason to.

In pop culture, cloning is used to bring people back from the dead. But that's not how it works. Cloning someone would only create a twin, not a replica, since identical twins have the same genetics, but not necessarily personalities. And a "Never Let Me Go" scenario, where organs are harvested from clones to save the rich, is not only unethical, but unnecessary. Why clone an entire person when you can just make the part you need? Something, theoretically, therapeutic cloning can solve.

Therapeutic cloning is almost identical to reproductive, except the cloned embryo is never implanted in a uterus. Instead, the embryo is cloned for the sole purpose of extracting stem cells. Stem cells have the incredible ability to turn into any other cell in the human body, which means they're great for developing new treatments for disease and have the potential to repair or regenerate tissues and organs.

But, no surprise, there are a lot of downsides with therapeutic cloning. The thing about stem cells is that they're a pretty limited resource. The most substantial source for embryonic stem cells? Three- to five-day-old embryos, cloned or otherwise. And when someone else's stem cells are transplanted into a patient, the body will sometimes fight them off like a disease. Some researchers believe that cloned stem cells, since they share the patient's DNA, would be less likely to be rejected. But this use case is still in the research stage.

And, finally, therapeutic cloning is an individualized treatment in a world where drug companies are more interested in standardized ones. And there are easier ways to create multipurpose cells nowadays, like the method for creating induced pluripotent stem cells. They're basically adult cells that have been reprogrammed to be a different type of cell.

Cibelli: The problem with therapeutic cloning, of course, is that you need a lab personnel that is qualified to do it, specific equipment to do it. Whereas the other technique, you can just buy a kit and one person can do it in a lab that has some expertise in tissue culture.

Narrator: Cloned cells still have an advantage when it comes to healthier mitochondria and the ability to grow into entire animals, whereas iPSCs often peter out. But since iPSCs safely and reliably do most everything but create entire living animals, why fund the harder, ethically ambiguous thing? So, cloning might actually have a bigger place in movies than it does in real life, because the money just isn't there. And just because we can do something doesn't mean we need to.

Ian: Your scientists were so preoccupied with whether or not they could, they didn't stop to think if they should.

Abby Tang: So, in the research for this video, I did come across one very interesting tidbit, and that is the announcement of cloned human baby Eve, who was born on December 26, 2002. And the source of this announcement is a company called Clonaid, which was formed in 1997 by the Raelian cult. And they're a cult that believes that humans were cloned from aliens and the only way for us to reach immortality is to clone ourselves. It's been 18 years, and we haven't gotten any proof that baby Eve exists or has ever existed, but the company is still alive and well. So if any proof does come through, we will update you.

Read the original here:
Why we still haven't cloned humans it's not just ethics - Business Insider - Business Insider

COVID-19 Impact and Recovery Analysis on Cell Freezing Media for Cell Therapy Market 2020-2026 by BioLife Solutions, Akron Biotechnology, GE…

By Embryonic Stem Cells

Heres recently issued report on the Global Cell Freezing Media for Cell Therapy Market that allows you to offer a brief analysis of the market size, demand, supply chain, distribution channels, futuristic trends, market growth elements and so on. It offers a comprehensive analysis of assorted business aspects like global Cell Freezing Media for Cell Therapy market trends, recent technological advancements, market shares, size and new innovations. What is more, this analytical knowledge has been compiled through knowledge searching techniques like primary and secondary analysis for Cell Freezing Media for Cell Therapy industry. Moreover, an professional team of researchers throws lightweight on numerous static additionally as dynamic aspects of the worldwide Cell Freezing Media for Cell Therapy market.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

Obtain sample copy of Cell Freezing Media for Cell Therapy market report: https://calibreresearch.com/report/global-cell-freezing-media-therapy-market-5285#request-sample

Geographically, the worldwide Cell Freezing Media for Cell Therapy market has been analyzed in numerous regions like North America, geographical region, geographical region, Asia-Pacific, Africa, Europe and Asian nation. The worldwide Cell Freezing Media for Cell Therapy market region is dominating this market among the forthcoming future. Worldwide Cell Freezing Media for Cell Therapy market is that the skilled and correct study of assorted business views like key players, key geographies, divers, restraints, opportunities and challenges. This global analysis report has been mass on the concept of assorted market segments and sub-segments associated with the worldwide market.

Global Cell Freezing Media for Cell Therapy market competition by prime manufacturers, with Cell Freezing Media for Cell Therapy sales volume, value (USD/Unit), revenue (Million USD) and market share for each manufacturer. The report provides an in-depth analysis of the worldwide Cell Freezing Media for Cell Therapy Market progressing to cut back time to plug for products and services, cut back operational value, improve accuracy and operational performance. Besides this, the report elaborates crucial aspects such as fresh product establishment, greater expenditure in R&D and increasing demand in the manufacturing differentiable growth opportunities in the Cell Freezing Media for Cell Therapy Market globally.

Checkout Inquiry For Buying or Customization of Cell Freezing Media for Cell Therapy Market Report: https://calibreresearch.com/report/global-cell-freezing-media-therapy-market-5285#inquiry-for-buying

The complete profile of the manufacturers are mentioned. And so the capability, production, price, revenue, cost, gross, margin of profit, sales volume, sales revenue, consumption, rate of growth, import and export, future strategies and therefore the technological developments that they are creating are also enclosed among the report. The historical knowledge and forecast knowledge from 2020 to 2026.

Leading companies reviewed in the Cell Freezing Media for Cell Therapy report are:

BioLife Solutions Akron Biotechnology GE Healthcare Thermo Fisher Scientific Biological Industries Merck WAK-Chemie Medical Zenoaq

The Cell Freezing Media for Cell Therapy Market report is segmented into following categories:

The Cell Freezing Media for Cell Therapy market report is segmented into Type by following categories; With FBS Without FBS

The Cell Freezing Media for Cell Therapy market report is segmented into Application by following categories; Human Embryonic Stem Cells CAR-T Cell Therapy Neural Stem Cell Therapy Mesenchymal Stem Cell Therapy Hematopoietic Stem Cell Transplantation Other

Checkout FREE Report Sample of Cell Freezing Media for Cell Therapy Market Report for Better Understanding: https://calibreresearch.com/report/global-cell-freezing-media-therapy-market-5285#request-sample

The report provides substantial knowledge relating to the market share that every one in every of these firms presently garner across this business, in tandem with the market share that they are expected to amass by the highest of the forecast period. Also, the report elaborates on details regarding the products manufactured by every of these companies, that may facilitate new entrants and outstanding stakeholders work on their competition and strategy portfolios. To not mention, their decision-making method is vulnerable to get easier on account of the actual fact that the Cell Freezing Media for Cell Therapy System market report additionally enumerates a gist of the products value trends and so the profit margins of each firm among the industry.

This will enable the readers to focus on Cell Freezing Media for Cell Therapy market product specifications, current competitive manufacturers in Cell Freezing Media for Cell Therapy market and also the market revenue with gain. Worldwide Industry Analyze Cell Freezing Media for Cell Therapy Market by competitive manufacturers, regions and applications of Cell Freezing Media for Cell Therapy market, forecast up to 2026. This report analyses the scope of Cell Freezing Media for Cell Therapy market. This will be achieved by Cell Freezing Media for Cell Therapy previous historical information, analysing qualitative insights info, demonstrable projections regarding global Cell Freezing Media for Cell Therapy market size.

View post:
COVID-19 Impact and Recovery Analysis on Cell Freezing Media for Cell Therapy Market 2020-2026 by BioLife Solutions, Akron Biotechnology, GE...

Why are scientists trying to manufacture organs in space? – The Conversation US

By Embryonic Stem Cells

This Bioculture System will let biologists learn about how space impacts human health by studying cells grown in the microgravity environment of the International Space Station.

Gravity can be a real downer when you are trying to grow organs.

Thats why experiments in space are so valuable. They have revealed a new perspective into biological sciences, including insights into making human tissues.

Gravity influences cellular behavior by impacting how protein and genes interact inside the cells, creating tissue that is polarized, a fundamental step for natural organ development. Unfortunately, gravity is against us when we try to reproduce complex three dimensional tissues in the lab for medical transplantation. This is difficult because of the intrinsic limitations of bio-reactors used on Earth.

I am a stem cell biologist and interested on brain health and evolution. My lab studies how the human brain is formed inside the womb and how alterations in this process might have lifelong consequences to human behavior, such as in autism or schizophrenia. Part of that work includes growing brain cells in space.

To build organized tissues in the lab, scientists use scaffolds to provide a surface for cells to attach based on a predetermined rigid shape. For example, an artificial kidney needs a structure, or scaffold, of a certain shape for kidney cells to grow on. Indeed, this strategy helps the tissue to organize in the early stages but creates problems in the long run, such as eventual immune reactions to these synthetic scaffolds or inaccurate structures.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

By contrast, in weightless conditions, cells can freely self-organize into their correct three-dimensional structure without the need for a scaffold substrate. By removing gravity from the equation, we researchers might learn new ways of building human tissues, such as cartilage and blood vessels that are scaffold-free, mimicking their natural cellular arrangement in an artificial setting. While this is not exactly what happens in the womb (after all the womb is also subject to gravity), weightless conditions does give us an advantage.

And this is precisely what is happening at the International Space Station.

These experiments help researchers optimize tissue growth for use in basic science, personalized medicine and organ transplantation.

But there are other reasons why we should manufacture organs in space. Long-term space missions create a series of physiological alterations in the body of astronauts. While some of these alterations are reversible with time, others are not, compromising future human spaceflights.

Studying astronauts bodies before and after their mission can reveal what goes wrong on their organs, but provides little insights on the mechanisms responsible for the observed alterations. Thus, growing human tissues in space can complement this type of investigation and reveal ways to counteract it.

Finally, all forms of life that we know about have evolved in the presence of microgravity. Without gravity, our brains might have evolved in a different trajectory, or our livers might not filter liquids as it does on Earth.

By recreating embryonic organ formation in space, we can anticipate how the human body in the womb would develop. There are several research initiatives going on in my lab with human brain organoids at ISS, designed to learn the impact of zero gravity on the developing human brain. These projects will have profound implications for future human colonization (can humans successfully reproduce in space?). These studies will also improve the generation of artificial organs that are used for testing drugs and treatments on Earth. Will better treatments for neurodevelopmental and neurodegenerative conditions that affects millions of people come from research in space?

See more here:
Why are scientists trying to manufacture organs in space? - The Conversation US

→←